This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DUCASSE, M. C. R. Articles by BAYARD, F. Search for Related Content PubMed PubMed Citation Articles by DUCASSE, M. C. R. Articles by BAYARD, F.

Shrinking of a Growth Hormone-Producing Pituitary Tumor by Continuous Subcutaneous Infusion of the Somatostatin Analog SMS 201-995

Departments of Endocrinology, Neuroradiology (A.B.), and Pediatrics (M.T.T.), CHR Rangueil, Chemin du Vallon Cedex F-31054 Toulouse, France
The Department of Neuroendocrinology, Sandoz Ltd., Clinical Research (A.G.H.) CH-4002 Basel, Switzerland

Address all correspondence and requests for reprints to: M. C. R. Ducasse, Department of Endocrinology, CHR Rangueil, Chemin du Vallon, Cedex F-31054 Toulouse, France.

SMS 201–995, a long-acting somatostatin analog, was given as the initial treatment to an acromegalic patient. SMS 201–995 (200 µg, sc, three times daily) reduced, but did not normalize, serum GH levels. Complete and prolonged control of GH secretion was obtained with a 600-µg daily continuous sc infusion (CSI), and the patient was treated in this way for 6 months. Rapid improvement of clinical signs and symptoms of acromegaly occurred, as did major tumor shrinkage. The other pituitary functions did not change. After 6 months, the daily SMS 201-995 dose was progressively reduced; GH secretion remained suppressed. After 12 months of treatment, GH secretion was controlled with a CSI of 100 µg SMS 201-995 daily, but not with two daily sc 100-µg injections. Further significant reduction in tumor size occurred. We conclude that CSI of SMS 201-995 resulted in constant GH normalization and marked clinical and morphological improvement. This form of treatment should be considered as an alternative to ablative treatment of acromegaly.

Received December 3, 1986.

This article has been cited by other articles:

				R. W. Hipkin, J. Friedman, R. B. Clark, C. M. Eppler, and A. Schonbrunn Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin Receptor J. Biol. Chem., May 23, 1997; 272(21): 13869 - 13876. [Abstract] [Full Text] [PDF]

				M. L. Vance and A. G. Harris Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide: Results of the International Multicenter Acromegaly Study Group Arch Intern Med, August 1, 1991; 151(8): 1573 - 1578. [Abstract] [PDF]

				S. Barakat and S. Melmed Reversible Shrinkage of a Growth Hormone-Secreting Pituitary Adenoma by a Long-Acting Somatostatin Analogue, Octreotide Arch Intern Med, June 1, 1989; 149(6): 1443 - 1445. [Abstract] [PDF]